Innovative heart device is safe and effective, study finds

"The Harpoon device was found to be remarkably safe and effective," says the study's principal investigator and an inventor of the device, James S. Gammie, MD, professor of surgery at UMSOM and chief of cardiac surgery at the University of Maryland Medical Center. "The device allowed the surgeons to precisely and effectively reduce the degree of mitral regurgitation without using an open-heart procedure. There were no deaths. Only one patient needed a blood transfusion, and there were no strokes, no need for pacemakers, no readmission to the ICU, and no reintubations," he says.

Thirty patients with a condition called mitral valve regurgitation (MR) were treated with the device at six clinical centers in Europe, sponsored by the manufacturer of the device, Harpoon Medical, Inc., Baltimore, Md., to determine whether the device meets essential European health and safety requirements.

Three patients required conversion to conventional open-heart mitral surgery, including two cases where poor imaging prevented accurate placement of the tool, while 27 met the primary endpoint. At six months, MR was mild or less in 85 percent (22/26) of patients successfully treated with H-MVRS. The repair was associated with restoration of normal valve function and improvement in the heart's ability to pump blood, according to the researchers, and the operative times for procedures using the device were approximately half those reported for conventional mitral valve repair.

Device Description

The H-MVRS is an investigational device. It does not have European CE marking and the U.S. Food and Drug Administration has not approved it for use in patients in the United States.

The H-MVRS is designed to treat degenerative MR, the most common type of heart valve disorder. In MR, a leaky valve lets blood travel in the wrong direction on the left side of the heart, causing shortness of breath, fluid retention, irregular heartbeats and fatigue. MR develops when the small fibrous cords that open and close the valve's flaps, known as leaflets, are broken or stretched, preventing them from closing tightly and causing the leaflets to bulge or prolapse upward toward the left atrium. The natural cords connect the valve flaps to muscles inside the heart that contract to close the mitral valve, which gets its name because its two flaps resemble a bishop's mitre.

The device anchors artificial cords on the flaps to take the place of the natural cords. The artificial cords are made of expanded polytetrafluoroethylene (ePTFE), a polymer commonly used as sutures in cardiac surgery.

Surgeons insert the device into the beating heart through a tiny opening in the ribcage and, using echocardiographic imaging, guide it to the surface of the defective mitral flaps. When the surgeon determines the optimal placement for an artificial cord, the device is actuated and a specially designed needle makes a tiny hole and sends the cord material through the flap. The needle is then withdrawn and the cord of ePTFE is tightened to form a double-helical knot to hold it in place. The sequence is repeated for the desired number of knots (usually four to six). The other end of the cord is adjusted for optimum length and tied to the outside layer of the heart, the epicardium.

"Over the past five years, our faculty has increasingly engaged in entrepreneurial and technology transfer activity -- with significant increases in the number of U.S. and foreign patents issued, technology inventions licensed and start-up companies formed," says UMSOM Dean E. Albert Reece, MD, PhD, MBA, vice president for medical affairs at the University of Maryland and the John Z. and Akiko K. Bowers Distinguished Professor. "This invention by Dr. Gammie is an excellent example of how new devices and therapies developed here have tremendous potential for treating patients and ultimately saving lives."

The device was previously tested in Poland. U.S. testing of the device may begin in 2018.

DISCLOSURE: The study was funded by Harpoon Medical, Inc. Dr. Gammie and three others on the research team report ownership of stock and/or options to purchase stock in Harpoon Medical. At the present time, the US Food and Drug Administration has not approved the H-MVRS for patients in the United States.